Dr Kamran Khursheed, Dr Kiran Ramzan, Dr Hassan Iqbal
Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in young women. It manifests itself in a variety of clinical ways and 55%–75% of patients with PCOS are infertile due to chronic anovulation. Aims and objectives: The main objective of the study is to analyze the role of letrozole in female ovulation induction with polycystic ovarian syndrome. Material and methods: This cross sectional study was conducted in Jinnah hospital, Lahore during April 2018 to September 2018 with the permission of ethical committee of hospital. The data was collected from 255 female patients who were suffering from PCOS. Letrozole 2.5 mg/day or CC 50 mg/day was administered from day 3 to day 7 of a spontaneous or progestogen-induced withdrawal of bleeding, plus HMG 75 IU on alternate days daily starting from day 7 and maintained for up to 10 days unless follicle maturity was reached so that human chorionic gonadotropin (hCG) could be administered. Results: The data were collected from 255 female patients. The mean age for this study was 27.28±3.45 years. No statistical difference could be detected for mean age, BMI, or menstrual patterns (amenorrhea or oligomenorrhea) among the three groups of patients. All groups had comparable proportions of primary or secondary infertility, and also the duration of infertility was not significantly different among the three groups. There was also no significant difference with regard to biochemical parameters such as FSH, LH, testosterone plasma levels, LH/FSH ratio, HOMA-IR, and AFC within the three groups. All patients studied had morphological features of PCOS on transvaginal sonographies. Conclusion: It is concluded that letrozole co-treatment with HMG not only reduced the duration of stimulation and total HMG dose needed for stimulation but also achieved a higher incidence of mono follicular growth, demonstrating that this protocol is effective and safe for ovarian induction.